April 2005
Seminar on EU/Asia-Pacific R&D collaboration
FP7 - The next step forward
Brussels/London: The third of a series of seminars on EU/Asia-Pacific science and technology collaboration titled "FP7 - The Next Step Forward" will take place on 10 May 2005 at the Royal Institute of International Affairs in London.
The last seminar on EU/Asia-Pacific collaboration saw the opening moves in the European Institution's debate on the likely shape of Europe's prime research and development blueprint, Framework Programme Seven (FP7), covering the period 2007-2013.
Distinguishing this latest in the series of events is its political setting: a tempering of the EU's overly ambitious Lisbon agenda, the aim of which is to render Europe the most competitive, knowledge-based economy in the world by 2010, with a more realizable concept of 'knowledge for growth'.
For registration and further information, please contact:
Marta Czerniawska
ISC
Park Leopold
Rue Wiertz, 50/28
B-1050 Brussels
Tel.: +32 (0)2 401 61 47
Fax: +32 (0)2 401 68 68
[email protected]
http://www.isc-europe.com
or
Dr Tony Hayward
[email protected]
Date & Time:
Tuesday 10th May 2005
18.00-20.30 hours.
Location:
Royal Institute of International Affairs, Chatham House, 10, St. James's Square, London SW1Y 4LE (Tel: 0207 957 5700).
Nearest Tube Stations: Piccadilly or Green Park
Editor's note:
Chair:
Dr. Peter J. Cozens, Principal, ProPharma Partners Limited
Speakers' and Chairman's Biographies:
Mr. Declan Kirrane, ISC, Brussels
Declan is founder and managing director of ISC, Brussels. ISC specialises in science and R&D public affairs, policy analysis and information dissemination.
In 1994 Declan established the CORDIS (Community Research and Development Information Service) on-line dissemination service at the beginning of FP4. Prior to that he was editor of the CORDIS News Service. Declan has variously edited the Commission's CORDIS focus, Innovation and Technology Transfer Newsletter and European Dialogue. He has also lectured widely on EU science policy and implementation programmes, and has developed R&D and innovation strategies for both public and private sector organisations.
ISC is currently contracted to the European Commission, US Department of Energy's Office of Science, EUREKA and the European Patent Office amongst others.
Two very useful URLs to be referenced are: www.isc-europe.com and www.cordis.lu/news.
Dr. Peter J. Cozens, ProPharma Partners Limited
Dr. Peter Cozens has worked for 22 years in the pharmaceutical industry. He is a scientifically qualified commercial development professional with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry. Experienced in all facets of identifying, negotiating and managing third party agreements in all major territories to facilitate strategic business expansion. Additional responsibility in managing Patents and Trademark functions, including patent law, has provided valuable experience in contractual and intellectual property law. Experience also includes management of an export function responsible for sales outside Europe and the US and responsibility for strategic marketing/business information. A molecular geneticist by training, in 1978 Dr. Cozens joined Ciba-Geigy (now Novartis) in Basel, Switzerland as a research scientist. In 1981 he moved to Wellcome Biotechnology Ltd. to work as a senior scientist in Molecular Biology and became leader of Wellcome's cytokine programme. From 1987 to 1991, whilst still at Wellcome, Dr. Cozens worked with Group Patents and Agreements on both patent litigation and licensing activities.
In 1991 he joined Medeva PLC where he became Executive Vice President, Business Development and Intellectual Property and a member of Medeva's Executive Management Committee. Dr Cozens' major achievement during this period was the building of Medeva's development pipeline. He was responsible for a series of in-licensing and out-licensing deals and acquisitions including partnerships with Janssen, Connetics Corporation, Targeted Genetics, Peptide Therapeutics, SmithKline Beecham, ML Labs, Aviron, Mayo Medical Ventures, Eurand and Chiroscience. Dr. Cozens also piloted the Biogen v Medeva patent case through several courts, culminating in the landmark House of Lords decision on the scope of patent claims.
Dr. Cozens is a member of the Intellectual Property Advisory Committee of the UK BioIndustry Association.